5
Participants
Start Date
June 30, 2006
Primary Completion Date
September 30, 2006
Study Completion Date
September 30, 2006
Megestrol acetate concentrated suspension 110 mg/mL
Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
Placebo
Placebo oral suspension, 5 mL once daily
Western Maryland Health System, Cumberland
Lowcountry Hematology & Oncology, PA, Mt. Pleasant
Innovative Medical Research of South Florida, Inc, Miami
Lead Sponsor
Collaborators (1)
PRA Health Sciences
INDUSTRY
Par Pharmaceutical, Inc.
INDUSTRY